An official website of the United States government
Fragile X
Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions Frequently Asked Questions (FAQs)
- Overview
- Request for Applications (RFA)
- Technical Assistance (TA) Webinar
- NIH RFA Contacts
- FAQs (Includes new FAQs as of 8/08/24)
Overview
NIH created the Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions Program in response to the Children’s Health Act of 2000.
Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions
In June 2024, NIH published RFA-HD-25-002 : Centers for Collaborative Research in Fragile X and FMR1-Associated Conditions (P50 Clinical Trial Optional).
Please note: In July 2024, NIH issued NOT-HD-24-026 : Notice to Extend the Application Receipt Date for RFA-HD-25-002, which extends the Request for Applications (RFA) deadline to August 20, 2024.
Genome Instability and Chromatin Remodeling Section
Weidong Wang , PhD, Chief
Dax Hoffman Lab: Section on Neurophysiology
The Hoffman group combines molecular, biochemical and electrophysiological approaches to investigate the roles of dendritic voltage-gated and neurotransmitter-activated channels in regulating neuronal development and synaptic plasticity in the mammalian hippocampus. To achieve this, the lab comprises an interdisciplinary team with expertise in cellular and molecular biology, biochemistry, electrophysiology, fluorescence imaging and computer modeling. These approaches allow us to assay channel function and regulation at the molecular scale in living cells.